Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition

Biogen will pay $172.50 per share in cash for Reata, which had a Thursday closing price of $108.

55), andThe company was founded in Plano, Texas in 2002 and focuses on antioxidative and anti-inflammatory drugsBiogen, a Massachusetts-based biotech company with a market cap of nearly $38 billion, has acquired three other companies in the last eight years. The $200 million

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion AcquisitionBiogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal.
مصدر: Forbes - 🏆 394. / 53 اقرأ أكثر »

Biogen to bulk up rare disease treatments with $7 billion Reata acquisitionBiogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.
مصدر: WashTimes - 🏆 235. / 63 اقرأ أكثر »